KYTX
Income statement / Annual
Last year (2023), Kyverna Therapeutics, Inc. Common Stock's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Kyverna Therapeutics, Inc. Common Stock's net income was -$60.37 M.
See Kyverna Therapeutics, Inc. Common Stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00
|
$7.03 M
|
$5.66 M
|
| Cost of Revenue |
$1.71 M |
$1.05 M |
$586,000.00 |
| Gross Profit |
-$1.71 M |
$5.97 M |
$5.07 M |
| Gross Profit Ratio |
0 |
0.85 |
0.9 |
| Research and Development
Expenses |
$49.92 M
|
$28.40 M
|
$25.85 M
|
| General & Administrative
Expenses |
$12.48 M
|
$8.01 M
|
$6.15 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.48 M
|
$8.01 M
|
$6.15 M
|
| Other Expenses |
$0.00 |
-$9,000.00 |
-$2,000.00 |
| Operating Expenses |
$62.41 M |
$36.41 M |
$32.00 M |
| Cost And Expenses |
$62.41 M |
$36.41 M |
$32.00 M |
| Interest Income |
$2.28 M |
$565,000.00 |
$1,000.00 |
| Interest Expense |
$187,000.00 |
$65,000.00 |
$3,000.00 |
| Depreciation &
Amortization |
$1.71 M
|
$1.05 M
|
$586,000.00
|
| EBITDA |
-$58.47 M
|
-$27.78 M
|
-$25.76 M
|
| EBITDA Ratio |
0 |
-3.95 |
-4.55 |
| Operating Income Ratio
|
0
|
-4.18
|
-4.66
|
| Total Other
Income/Expenses Net |
$2.04 M
|
$491,000.00
|
-$4,000.00
|
| Income Before Tax |
-$60.37 M |
-$28.89 M |
-$26.35 M |
| Income Before Tax Ratio
|
0
|
-4.11
|
-4.66
|
| Income Tax Expense |
$0.00 |
$56,000.00 |
$1,000.00 |
| Net Income |
-$60.37 M |
-$28.89 M |
-$26.35 M |
| Net Income Ratio |
0 |
-4.11 |
-4.66 |
| EPS |
-0.0001 |
-1.12 |
-1.02 |
| EPS Diluted |
-0.0001 |
-1.12 |
-1.02 |
| Weighted Average Shares
Out |
$673.62 M
|
$25.80 M
|
$25.80 M
|
| Weighted Average Shares
Out Diluted |
$673.62 M
|
$25.80 M
|
$25.80 M
|
| Link |
|
|
|
